Semalytix’s PatientGPT Broadens the Scope of AI ML and LLMs in the Life Science Industry

Semalytix’s PatientGPT is a patient-centric Large Language Model (LLM) approach for Life Sciences applications. The new generative AI tool showcases a smart interplay between supervised machine learning and LLMs that are trained on millions of real-time patient experience data sourced in 26 different languages. According to the company that made PatientGPT, the new generative AI tool is capable of replacing all the existing 6 months’ worth of research and documentation within a few seconds. Considered as a milestone in patient-centric healthcare and drug development industry, PatientGPT could surpass all the previously known capabilities of AI and machine learning in the life sciences industry.

AIThority readers would know that this is not the first PatientGPT in the modern healthcare industry. Earlier, PatientGenie had also launched its version of “PatientGPT”. PatientGenie’s AI platform is directed at patients and healthcare managers seeking better personalized responses from the existing healthcare systems while navigating through the different processes at various stages of diagnosis, treatment and follow-ups.

Generative AI tools built on Large Language Models (LLMs) are simplifying drug development process in the pharmaceutical industry. Despite rapid advancements in the pharma industry in the post-pandemic era, a majority of drug developers are still fighting it out for efficacy and timely delivery. By bringing in supervised ML and LLMs to life sciences, PatientGPT, a new kind of generative AI model, could accelerate the entire lifecycle in a safer environment for handling sensitive patient data. This new AI tool could complement Semalytix’s real-world evidence generation platform, called Pharos.

Semalytixs’ co-founder and Chief Product Officer, Janik Jaskolski said, “We can not only analyze but also precisely query the effects of any medication based on patient experiences and unmet needs worldwide, down to the smallest detail. By the end of the year, we will have over 50 million patient data points in our patient experience data archive, which our own LLM solution will be tuned with. This allows us to gain exact insights into how people live with diseases and generate crucial new knowledge for patient-focused drug development.”

Benefits of PatientGPT

Janik’s colleague and co-founder at Semalytix, Prof. Dr. Philipp Cimiano (Chief Technology Officer) added, “PatientGPT truly unlocks the huge potential of patient experience data that will help shape new therapies and authentically and continuously answer what patients need most.”

Janik said, “The most popular example from recent history is the accidental invention of the potent drug V***** in 1998, which was originally a side effect of the tested hypertension medication and repurposed based on patient experiences. Thanks to modern technologies, this kind of learning can now be amplified. “With access to over 100 million sources in 26 different languages, and combining patient experiences from around the world over the past 10 years, the treasure of global patient knowledge already resides in our Pharos platform.”

A well-oiled and highly data-intensive supervised AI framework governs the working and outcomes of PatientGPT at Semalytix. This ensures PatientGPT outcomes are accurate and hallucination-free, which makes it easier for the analytics team at life sciences organizations to fact-check every bit of information in real time. The new AI tool would boost evidence-based drug development for chronic diseases such as cancer, diabetes, and mental illness. Founded in 2015, this AI pioneer is already fulfilling the needs of the top 20 pharma companies.